|
Recent Developments |
|
11-FEB-19
Aurobindo Pharma, a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, today announced that it has closed the acquisition of Apotex's commercial operations and certain supporting infrastructure in five European countries.
18-JAN-19
Aurobindo Pharma, announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum p... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Aurobindo Pharma, plans to complete restructuring and expansion programme during Q4 FY 2001-02. The company plans to achieve a turnover of above Rs 4,000 crore by FY 2005-06 with formulations accounting for 30 per cent. Joint ventures in US and China are expected boost the company`s international revenues. Srinivas Lanka |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015 (12) | 31-Mar-2014 (12) | | Net sales | 89223.80 | 80180.00 | 70495.70 | | Other Income | 392.90 | 423.20 | 328.70 | | Total Income | 89616.70 | 80603.20 | 70824.40 | | Cost of goods sold | 67171.50 | 58446.80 | 51912.30 | | OPBDIT | 22445.20 | 22156.40 | 18912.10 | | PAT | 16196.70 | 15163.40 | 11720.90 | | Gross Block | - | - | - | | Equity capital | 585.20 | 292.00 | 291.50 | | EPS (Rs.) | - | 52.01 | 40.24 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 9.80 - 24.59 | 3.44 - 13.54 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 25.0 | 27.5 | 26.7 | | Net margin (% of OI) | 18.1 | 18.8 | 16.5 |
|
|
Detailed Financials
|
|
|
|
|
